We utilize a broad range of IT and AI technologies in various drug development activities. NEC develops cancer vaccines using AI technologies. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.